NCT00900133View on ClinicalTrials.gov

Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

December 31, 2006

Conditions
Breast Cancer
Interventions
OTHER

immunoenzyme technique

Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.

OTHER

laboratory biomarker analysis

Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.

Trial Locations (1)

44106

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00900133 - Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer | Biotech Hunter | Biotech Hunter